Clinical Trials Logo

Prostate Cancer Recurrent clinical trials

View clinical trials related to Prostate Cancer Recurrent.

Filter by:

NCT ID: NCT03553602 Recruiting - Clinical trials for Prostate Cancer - Recurrent

BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy

BEACON
Start date: May 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) to the pelvis and 6 months of hormonal therapy, otherwise known as short term androgen deprivation therapy (STAD), as treatment for prostate cancer that has come back in the prostate and pelvic lymph nodes after prior radiotherapy. The study will examine the side effects of the treatment as well as the ability of the treatment to get rid of the cancer. This involves the placement of a radioactive material in the affected area of the prostate temporarily, and then is subsequently removed using a minimally invasive technique. Participants will also receive external radiation for 5 weeks targeting the pelvis and giving a higher dose each day to the suspicious lymph nodes on PET scan. Radiation therapy will start approximately 2 months after the start of the Androgen Deprivation Therapy (hormone therapy). The hormone therapy consists of two medications, an oral medication taken daily 2 months before starting radiation therapy until the last of the radiation therapy and an injection of a medication which is given 2 months prior to the start of radiation. Patient are then followed at specific time intervals to evaluate the treatment side effects and cancer control

NCT ID: NCT03507595 Recruiting - Clinical trials for Prostate Cancer Metastatic

Evaluation of the Metastasis and Recurrence of Prostate Cancer

Start date: September 1, 2017
Phase:
Study type: Observational

This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging methods (whole body bone scintigraphy and MRI) and molecular imaging methods (11C-choline PET/CT),we hope to find the advantages of 18F-PSMA PET/CT in the diagnosis and metastases of prostate cancer, and lay the foundation for the further clinical transformation.

NCT ID: NCT01938339 Recruiting - Clinical trials for Prostate Cancer Recurrent

Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer

Start date: May 2012
Phase: N/A
Study type: Interventional

To development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (PET/MR) in prostate cancer - to establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer - to establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer and early detection of recurrent prostate cancer